Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – October 16th – November 15th, 2025

Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. – October 16^th – November 15^th, 2025

Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. Summit Therapeutics, a biopharmaceutical company that discovers, develops, and commercializes novel antibiotics for serious infectious diseases, received $500 million of development capital through a private placement.
2. Tharimmune, a biotechnology company that develops a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases, received $545 million of development capital through a private placement.

Merger/Acquisition

3. 89bio, a US-based clinical-stage biopharmaceutical company that develops and commercializes therapies for the treatment of liver and cardiometabolic diseases, was acquired by Roche for $1.324 billion.
4. Gilgamesh Pharmaceuticals, mental health science-focused biotechnology platform that develops novel compounds and treats neurological disorders, was acquired by AbbVie for $1.2 billion.
5. Metsera, a clinical-stage biotechnology company that develops next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions, was acquired by Pfizer for $10 billion.

Later Stage VC

6. Corner Therapeutics, biotechnology research services that stimulate exceptional memory T cells for lifelong immunity, raised $58.51 million of Series A venture funding.
7. Iambic, artificial intelligence-driven platform that addresses the most challenging design problems in drug discovery, leveraging technology innovations, raised $99.27 million of Series B3 venture funding.
8. MarvelBiome, biopharmaceutical technology company that harnesses the power of microbes for treating various human diseases, raised $39.56 million through the combination of Series C, Series C-1, and Series C-2 venture funding.

Early Stage VC

9. Braveheart Bio, a cardiac myosin inhibitor that treats cardiovascular disorders, raised $185 million of Series A venture funding.
10. NewLimit, precision medicines for epigenetic reprogramming to restore youthful function in aging cells, raised $130 million of Series B venture funding.

#castleplacement #capitalraising #privateequity #venturecapital #investment #pharma #drug #drugdiscovery #drugdelivery

Diana Ruddy

Managing Director

Please contact me if you have any questions or would like to discuss your capital raise:

Email: druddy@castleplacement.com

(C) (406) 868-3218

Send us a message:

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.